394 related articles for article (PubMed ID: 28114624)
1. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
Rose SL; Highland J; Karafa MT; Joffe S
JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Potential Conflicts of Interest among Otolaryngologic Patient Advocacy Organizations in 2016.
Kondamuri NS; Rathi VK; Naunheim MR; Sethi RV; Miller AL; Varvares MA
Otolaryngol Head Neck Surg; 2019 Dec; 161(6):967-969. PubMed ID: 31479391
[TBL] [Abstract][Full Text] [Related]
3. A Content Analysis of Patient Advocacy Organization Policies Addressing Institutional Conflicts of Interest.
Brems JH; McCoy MS
AJOB Empir Bioeth; 2019; 10(4):215-221. PubMed ID: 31593523
[No Abstract] [Full Text] [Related]
4. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
Li DG; Singer S; Mostaghimi A
JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
Kang SY; Bai G; Karas L; Anderson GF
Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
[TBL] [Abstract][Full Text] [Related]
6. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.
Rose SL
J Law Med Ethics; 2013; 41(3):680-7. PubMed ID: 24088159
[TBL] [Abstract][Full Text] [Related]
7. When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest.
Ehrlich O; Wingate L; Heller C; de Melo-Martin I
BMC Med Ethics; 2019 Dec; 20(1):96. PubMed ID: 31847854
[TBL] [Abstract][Full Text] [Related]
8. Industry Support of Patient Advocacy Organizations: The Case for an Extension of the Sunshine Act Provisions of the Affordable Care Act.
McCoy MS
Am J Public Health; 2018 Aug; 108(8):1026-1030. PubMed ID: 29927655
[TBL] [Abstract][Full Text] [Related]
9. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study.
Moynihan R; Albarqouni L; Nangla C; Dunn AG; Lexchin J; Bero L
BMJ; 2020 May; 369():m1505. PubMed ID: 32461201
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
[TBL] [Abstract][Full Text] [Related]
11. Policies on faculty conflicts of interest at US universities.
Cho MK; Shohara R; Schissel A; Rennie D
JAMA; 2000 Nov; 284(17):2203-8. PubMed ID: 11056591
[TBL] [Abstract][Full Text] [Related]
12. Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops.
Miller SL; Haslam A; Prasad V
Eur J Clin Invest; 2024 Jun; 54(6):e14184. PubMed ID: 38407501
[TBL] [Abstract][Full Text] [Related]
13. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.
Parker L; Fabbri A; Grundy Q; Mintzes B; Bero L
BMJ; 2019 Dec; 367():l6694. PubMed ID: 31831471
[TBL] [Abstract][Full Text] [Related]
14. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
Hughes D; Williams-Jones B
Healthc Policy; 2013 Aug; 9(1):52-64. PubMed ID: 23968674
[TBL] [Abstract][Full Text] [Related]
15. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
[TBL] [Abstract][Full Text] [Related]
16. Financial relationships between patient and consumer representatives and the health industry: A systematic review.
Khabsa J; Semaan A; El-Harakeh A; Khamis AM; Obeid S; Noureldine HA; Akl EA
Health Expect; 2020 Apr; 23(2):483-495. PubMed ID: 31858662
[TBL] [Abstract][Full Text] [Related]
17. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study.
Elder K; Turner KA; Cosgrove L; Lexchin J; Shnier A; Moore A; Straus S; Thombs BD
CMAJ; 2020 Jun; 192(23):E617-E625. PubMed ID: 32538799
[TBL] [Abstract][Full Text] [Related]
18. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
Kerridge I; Maguire J; Newby D; McNeill PM; Henry D; Hill S; Day R; Macdonald G; Stokes B; Henderson K
Intern Med J; 2005 Apr; 35(4):206-10. PubMed ID: 15836497
[TBL] [Abstract][Full Text] [Related]
19. Industry funding of patient and health consumer organisations: systematic review with meta-analysis.
Fabbri A; Parker L; Colombo C; Mosconi P; Barbara G; Frattaruolo MP; Lau E; Kroeger CM; Lunny C; Salzwedel DM; Mintzes B
BMJ; 2020 Jan; 368():l6925. PubMed ID: 31969320
[TBL] [Abstract][Full Text] [Related]
20. Guideline funding and conflicts of interest: article 4 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
Boyd EA; Akl EA; Baumann M; Curtis JR; Field MJ; Jaeschke R; Osborne M; Schünemann HJ;
Proc Am Thorac Soc; 2012 Dec; 9(5):234-42. PubMed ID: 23256165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
